ClinicalTrials.gov
ClinicalTrials.gov Menu

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00082095
Recruitment Status : Terminated (The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months)
First Posted : April 30, 2004
Last Update Posted : October 9, 2014
Sponsor:
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2005
  Actual Study Completion Date : December 2005